As director of the Genomes2Veterans research program at the Veterans Affairs (VA) Boston Healthcare System, Jason Vassy, MD, MPH, SM, bridges the expertise of Genomes2People and the mission of bringing 21st century medical care to Veterans.
Current Genomes2Veterans research projects:
Integrating Pharmacogenetics in Clinical Care (I-PICC) Study
Funding: U.S. Department of Veterans Affairs Office of Research & Development IK2-CX001262
Project Manager: Charles Brunette, PhD
The I-PICC Study is a pragmatic randomized controlled trial of pharmacogenetic testing for statin myopathy risk in the eight primary care practices across VA Boston. Statin-naïve patients at higher risk for cardiovascular disease are randomly assigned at the point-of-care to have their primary care providers receive their SLCO1B1 genotype results at baseline or at the end of the study. Patients are followed in the electronic health record for 12 months for outcomes including cholesterol levels, statin-associated muscle symptoms, and concordance with cardiovascular disease and pharmacogenetic prescribing guidelines.
For more detailed information about the I-PICC Project, including study design and outcome measures, visit our clinical trial page:
PRecision medicine In MEntal Health (PRIME) Care Study
Funding: U.S. Department of Veterans Affairs Office of Research & Development SDR 16-348
Research Coordinator: Sanjay Advani, MA
VA Boston is one of 19 VA sites across the country participating the PRIME Care Study, a randomized controlled trial of pharmacogenetic testing to guide antidepressant prescribing among patients with major depressive disorder. The PRIME Care Study is testing the hypothesis that pharmacogenetics-guided prescribing will improve rates of depression remission compared to current standard of care.
For more detailed information about the PRIME Care Study, including study design and outcome measures, visit our clinical trial page:
The GenoVA Study: Pragmatic Randomized Trial of Polygenic Risk Scoring for Common Diseases in Primary Care
Funding: NIH, National Human Genome Research Institute 1 R35 HG010706-01
Project Manager: Ashley Antwi, MPH, CHES
The GenoVA Study is a pragmatic randomized controlled trial in which primary care patients without a known diagnosis of any one of 6 target diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus, colorectal cancer, breast cancer, and prostate cancer) will undergo clinical genotype testing to calculate their polygenic risk scores (PRS) for these 6 diseases. Patient-participants with at least one PRS indicating high-risk (odds ratio, ORPRS, > 2.5) will be randomized to have them and their primary care provider receive their high-PRS results at baseline or after a 24-month observation period, reported along with evidence-based screening and management recommendations. Patients will be observed for 24 months for the primary clinical outcome of time-to-diagnosis of any of the 6 target diseases.
Funding: Denny Sanford and Sanford Health
Project Coordinators: Ashley Antwi, MPH, CHES and Brian Walker, MPP
VA Boston is currently one of the first VA sites across the country participating in the PHASER program, a clinical implementation program and precision health initiative that provides preemptive pharmacogenomic (PGx) testing to current VA patients. The purpose of the program is to improve Veteran patients’ access to appropriate treatments and reduce adverse drug reactions.
Genomes2Veterans research team:
Sanjay Advani, MA
Ashley Antwi, MPH, CHES
Charles Brunette, PhD
Morgan Danowski, MS, CGC
Jason Vassy, MD, MPH, SM
For Genomes2Veterans scientific papers and media coverage, visit the link below.